Abstract

One needs to think outside of the box, as one of us (Ronald B Luftig) learned from many years as a mathematician, and a biophysicist.

In this short Review, the need to focus on producing high levels of neutralizing antibodies (NAbs) to incoming and conformationally altered virus after it has bound to CD4+ cells is essential.

Increasing the number of gp120 molecules on the surface of L-2 particles, could allow for an enhanced number of NAbs.

The attempt at increasing CD8+ T cell responses in recent vaccine trials has not worked perhaps because it may have allowed HIV to enter into remote sanctuaries. Our approach focuses on increasing NAbs, before high levels of CD8+ T cells are produced.

Background

It has now become a frequent ritual to read of the newest clinical trial failure and yet the same paradigm goes on [1]. Most recently the promising Phase III trial termed STEP, started in December 2004 was stopped [2]. The strategy was to boost killer T-cells in order to provide a broad-based vaccine and protect high-risk individuals against HIV strains world-wide. An adenovirus vector shuttled 3 HIV genes into the body. Surprisingly, there were more HIV infections in the vaccinees as compared to those in the placebo group [3].

Despite this set-back, trials are starting this Fall using a similar strategy. What is wrong is that vaccinology is not only a science but an art and one needs to take a step back from using the same failed approaches.

We propose that one needs to think differently by presenting defective HIV particles (L-2) which contain 7 to 10-fold more gp120 spikes on their surface in a prime (plasmid pl2)-boost (L-2 particle-Figure 1) strategy. These particles are unique in that they lack several core components of mature virions and present an increased number of gp120 particles (trimeric spikes) as compared to wild type (Table 1). Although mechanistically unclear the increase in surface ENV on these particles is likely due to stabilization of the trimers in the membranes by mutations in the gp41 C-terminus [4] and possibly due to a truncated 56 amino acid NH2 terminal Nef (STOP codon exactly at cleavage site of HIV protease in wild type virus). Preliminary cryo-electron microscopic analysis of L-2 (Figure 2A) relative to HIV (Figure 2B) shows enhanced gp120 spikes (Figure 2A, red arrows) which substantiates the TEM images (Figure 1) and immunoblotting studies that detailed the enrichment of Env on L-2 [5] and pL2 [6]. The double membrane of immature gag in L-2 particles noted by Wright, et al [7] in HIV is also clearly visible (Figure 2, blue arrows). We thank the Lab of Dr. Kenneth Roux for...
contribute Figure 2, using a cryo-EM method they developed to observe enhanced numbers of spikes on an SIV gp41 mutant [8].

Therefore we propose that recombinant L-2 particles will be an excellent scaffold for the presentation of native Env trimers. This approach allows for the flexibility of a) building multi-clade Env expressing particles. The new constructs would include Clades C, AE and circulating recombinant forms (CRFs) from China and Africa [9,10] Env in pL2. Currently, we are testing Clades C and AE to verify that the L-2 backbone for these new Clades still allows for the large number of trimers per particle observed with L-2. If this doesn’t work, we will use a different consensus Env expression construct [11] or b) insert structure-based snapshots [12]. It is plausible that these approaches will improve upon current vaccine immunogens by displaying Env trimers in their native context and through stabilized multimerization of Env antigen on L-2 particles.

Simultaneously an intranasal spray is to be administered in order to protect CD4 T-cells in the GALT. The rapid targeting of HIV to the gut mucosa has been well demonstrated in monkeys and recent results show it is only necessary but not sufficient for disease [13].

The properties of L-2 particles are depicted in Table 1 (detailed sequencing manuscript of this data submitted by Zhong, Ikuta and Luftig).

In the model proposed we are thinking about HIV vaccination in a different way. It is important to elicit neutralizing antibodies [14], protect destruction of the GALT and COMBINE this with a potent CTL-based vaccine compo-
Table 1: Compare and contrast L-2 with HIV

| Protein | L-2 | HIV | Virion | L-2 | HIV |
|---------|-----|-----|--------|-----|-----|
| Gag     | (+)* | (+)** | Genome RNA | (+) | (+) |
| Pol     | (-)  | (+)  | Infectivity | (-) | (+) |
| Vif     | (-)  | (+)  | Envelope S | 7–10 times Normal | Normal |
| Vpr     | (-)  | (+)  | Particles  | Doughnut like | Normal |
| Vpu     | (+)  | (+)  | Antigenicity | (+) | (+) |
| Tat     | (+)  | (+)  | CD4+ Cell Fusion | Yes | Yes |
| Rev     | (+)  | (+)  |          |        |     |
| Env     | (+)  | (+)  |          |        |     |
| Nef     | (-)  | (+)  |          |        |     |

* gag uncleaved ** gag cleaved

Several years ago, Drs. Ikuta and Goto discovered a subline of HIV-infected cells producing protease deficient, defective particles that they called L-2 ([5] and Fig 1). Figure 1 displays a cartoon of L-2 and shows a TEM with several particles containing multiple spikes inside the cartoon. We suggested to Dr. Ikuta that L-2 looked exactly like the doughnut shaped, protease deficient mutants of retroviruses we had studied in the murine system; he considered it was a mutant in RT, since there was no measurable RT activity. Our labs then both sequenced the PR gene nucleic acid from L-2 cells using RT-PCR and found a T nucleotide insertion about one third from the NH2 terminus equivalent of the gene, leading to a STOP codon several nucleotides distant. Thus, there was no PR, RT or INT activity. When the genome of L-2 was sequenced in 1997 it was found that there were 5 mutations [15]. This formed the basis of a patent I received [16]. In 2007 a complete RT-PCR derived DNA sequencing of L-2 particles and its plasmid pL2 was performed. As noted, L-2 particles are unique in that they lack several core components of mature virions. An additional three mutations were found in 2007 (Table 1).

After many years we learned from monkey studies performed by the New England Primate and Harvard groups that mutated SIV will eventually revert back to wild type. However, L-2 particles have 8 mutational differences from HIV (embodied in the 5 differences noted in Table 1). All are related structurally and provide a lock and key effect that might slow down reversions until broad memory B and T-cells responses are generated. Protection of the GALT and provision of a potent CTL-based component would complement these events.

Further, if a high risk individual is infected with a new CRF or Clade other than B, this may be solved by constructing through cassette mutagenesis; multiple new particles based on a backbone of L-2 defective mutant plasmid DNAs mixed together.

AIDS researchers may reasonable argue, that even if multiple broadly neutralizing antibodies did exist, once a high risk patient was infected with HIV, it could avoid neutralization or CTL killing and enter into DNA quiescent T-cells and re-emerge unscathed. However, by an unknown mechanism if L-2 RNA is present within T-cells it serves as a stealth agent and wild type HIV picks up the L-2 envelope with multiple gp120 spikes [17]. This further enhances an opportunity in the body for HIV to be neutralized by pre-existing broadly neutralizing sera or CTL’s.

Finally, of great concern is that we don’t want to repeat the errors of other excellent AIDS researchers and grow the virus in human T-cell lines, which pick up MHC Class I, II and other components. Thus, L-2 which originated in a human T cell line is being grown in non-human cell lines.

In addition, a recent paper [18] refers to the possibility that if potent T-cell responses are boosted, HIV may move to a sanctuary resulting in persistence of the virus.

The reason for writing this article is not to guarantee an HIV/AIDS vaccine, but to stimulate new thinking for such a vaccine.

Competing interests
The author(s) declare that they have no competing interests.

Authors’ contributions
RBL drafted MSS. QZ performed experiments related to MSS.

References
1. Girard MP, Osmanov SK, Kieny MP. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 2006, 24:4062-4081.
2. Cohen J: AIDS research. Promising AIDS vaccine’s failure leaves field reeling. Science 2007, 318:28-29.
3. Fauci AS: The Release of New Date from the HVTN 502 (STEP) HIV Vaccine Study. NIAID NIH 2007 [http://www3.niaid.nih.gov/about/directors/news/step_11707.htm].
4. Kinomoto M, Yokoyama M, Sato H, Kojima A, Kurata T, Iiuwa K, Sata T, Tokunaga K: Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitor. J Virol 2005, 79:6096-6104.
5. Ohki K, Kishi Y, Nishino Y, Sumiya M, Kimura T, Goto T, Nakai M, Ikuta K. Noninfectious doughnut-shaped human immunodeficiency virus type 1 can induce syncytia mediated by fusion of
the particles with CD4-positive cells. J Acquir Immune Defic Syndr 1991, 4:1233-1240.
6. Kinomoto M, Mukai T, Li YG, Iwabu Y, Warachit J, Palacios JA, Ibrahim MS, Tsuji S, Goto T, Ikuta K: Enhancement of human immunodeficiency virus type 1 infectivity by replacing the region including Env derived from defective particles with an ability to form particle-mediated syncytia in CD4+ T cells. Microbes Infect 2004, 6:911-918.
7. Wright ER, Schoeller JB, Ding HJ, Kieffer C, Fillmore C, Sundquist WI, Jensen GJ: Electron cryotomography of immature HIV-1 viruses reveals the structure of the CA and SP1 Gag shells. Embo J 2007, 26:2218-2226.
8. Zhu P, Liu J, Bass Jr., Chertova E, Lifson JD, Grise H, Olek GA, Taylor KA, Roux KH: Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006, 441:847-852.
9. Zhang Y, Lu L, Ba L, Liu L, Yang L, Jia M, Wang H, Fang Q, Shi Y, Yan W, Chang G, Zhang L, Ho DD, Chen Z: Dominance of HIV-1 subtype CRF01 AE in sexually acquired cases leads to a new epidemic in Yunnan province of China. PLoS Med 2006, 3:e443.
10. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, Mlisana K, Karim SA, Hong K, Greene KM, Biliska M, Zhou J, Allen S, Chomba E, Mulenga J, Wvalica C, Gao F, Zhang M, Korber BT, Hunter E, Hahn BH, Montefiori DC: Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Viral 2006, 80:11776-11790.
11. Haynes BF, Montefiori DC: Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines 2006, 5:347-363.
12. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, Harrison SC: Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 2005, 433:834-841.
13. Pandrea IV, Gautam R, Ribeiro RM, Brenchley JM, Butler IF, Pattison M, Rasmussen T, Marx PA, Silvestri G, Lackner AA, Perelson AS, Douek DC, Veazey RS, Aperet C: Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence. J Immunol 2007, 179:3035-3046.
14. Law M, Cardoso RM, Wilson IA, Burton DR: Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J Viral 2007, 81:4272-4285.
15. Bahmani MK, Kameoka M, Nakaya T, Fujinaga K, Zhong Q, Takahashi H, Nakano T, Nakai M, Ueda S, Jones IM, Luftig RB, Ikuta K: Production of doughnut-shaped, protease-defective particles from a human T cell clone carrying a provirus with specific mutations in the env, pol, vpr, and nef genes. AIDS Res Hum Retroviruses 1997, 13:523-526.
16. Luftig RB: Non-infectious, protease defective HIV particles and nucleic acid molecules encoding thereof. United States Patent 2001, US 6,328,976 (B1):1-42.
17. Iwabu Y, Goto T, Tsuji S, Warachit J, Li GM, Shoji S, Kameoka M, Ikuta K: Superinfection of human immunodeficiency virus type 1 (HIV-1) to cell clone persistently infected with defective virus induces production of highly cytopathic HIV-1. Microbes Infect 2006, 8:1773-1782.
18. Recher M, Lang KS, Navarini A, Hunziker L, Lang PA, Fink K, Freigang S, Georgiev P, Hangartner L, Zellweger R, Berghalser A, Hegazy AN, Eschli B, Theodarides A, Jeker LT, Merkler D, Odermatt B, Hersberger M, Hengartner H, Zinkernagel RM: Extralymphatic virus sanctuaries as a consequence of potent T-cell activation. Nat Med 2007, 13:1316-1323.